Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- METI to Investigate Needs for R&D Promotion Taxation System
October 30, 2006
- SELF-MEDICATION NEWS IN BRIEF
October 23, 2006
- JPA to Launch Data Sheet Database in Early December
October 23, 2006
- SURVEY 2 articles
October 23, 2006
- Shionogi, Hokkaido Univ. Jointly Create Drug Discovery Center
October 23, 2006
- Baxter Announces Results of PI/II Clinical Trial of Cell-Based H5N1 Vaccine
October 23, 2006
- Pulmicort Respules to Popularize Inhalant Steroids in Japan: AstraZeneca
October 23, 2006
- REGULATORY NEWS IN BRIEF -2-
October 23, 2006
- Taiho: Sales Up 2.0%, Strong Growth of TS-1, Global Business Props Up Overall Performance
October 23, 2006
- New Mechanism Leading to Development of Anticancer Drugs Discovered by AIST Researchers
October 23, 2006
- Hisamitsu: Sales Up 9.9%, Net Profits Up 10.3%
October 23, 2006
- Understanding of Public Indispensable to Utilize PGx: Prof. Tsuya
October 23, 2006
- Expansion of GE Drug Market Pushes Up Nichi-iko's Sales, Profits
October 23, 2006
- R&D NEWS IN BRIEF
October 23, 2006
- BUSINESS NEWS IN BRIEF
October 23, 2006
- NEW PRODUCTS
October 23, 2006
- SEMINAR
October 23, 2006
- 21st Scientific Meeting of the International Society of Hypertension
October 23, 2006
- NEW PRODUCTS
October 23, 2006
- Iressa as a Drug for 21st Century Personalized Medicine
October 23, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…